Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Laboratory for Molecular Medicine, |
RCV000151268 | SCV000199188 | likely pathogenic | Hypertrophic cardiomyopathy | 2013-08-27 | criteria provided, single submitter | clinical testing | The Pro838Gln variant in MYH7 has now been identified by our laboratory as a de novo variant in 1 neonate with HCM. It has not been identified in large populati on studies. This variant was predicted to be pathogenic using a computational to ol clinically validated by our laboratory. This tool's pathogenic prediction is estimated to be correct 94% of the time (Jordan 2011). Additional computational analyses (biochemical amino acid properties, conservation, AlignGVGD, PolyPhen2, and SIFT) suggest that this variant may impact the protein, though this informa tion is not predictive enough to determine pathogenicity. In addition, another v ariant at this position, Pro838Leu, has been identified as a de novo variant in 2 infants with RCM (Karam 2008; LMM unpublished data) and is classified as patho genic by our laboratory. In summary, the available data suggests that the Pro838 Gln variant is likely pathogenic, though additional studies are required to full y establish its clinical significance. |